Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
03.06. | Sareum Holdings - A decisive step towards Phase II | 230 | Edison Investment Research | Sareum Holdings has reported the initiation of toxicology studies required ahead of the Phase II studies for its lead TYK2/JAK1 asset, SDC-1801. We view this as a key milestone in SDC-1801's development... ► Artikel lesen | |
29.05. | Sareum starts toxicology studies for lead inhibitor | - | Sharecast | ||
29.05. | Sareum Holdings PLC - Initiation of Toxicology Studies for SDC-1801 | - | RNS | ||
28.04. | Sareum Holdings PLC - Update on TYK2/JAK1 and SRA737 Programmes | 1 | RNS | ||
24.04. | Sareum Holdings PLC - Exercise of Warrants | 1 | RNS | ||
10.04. | Sareum Holdings - Broader pipeline, bigger milestones | 254 | Edison Investment Research | Sareum Holdings' H125 results (to 31 December 2024) summarised a period of operational progress and an improved capital position, with successful fund-raising. Since the completion of the Phase I trial... ► Artikel lesen | |
27.03. | Sareum-Vorsitzender erhöht Anteil durch Aktienkauf | 1 | Investing.com Deutsch | ||
27.03. | Sareum chairman boosts stake with share purchase | 3 | Investing.com | ||
SAREUM Aktie jetzt für 0€ handeln | |||||
27.03. | Sareum Holdings PLC - Director's Dealing | - | RNS | ||
25.03. | Sareum Holdings PLC - Sareum Half-Year Report | - | RNS | ||
20.03. | Sareum Holdings PLC - Notice of HY Results and Investor Presentation | 1 | RNS | ||
14.03. | Sareum Holdings - New fund-raise and licence signal active 2025 | 383 | Edison Investment Research | Sareum Holdings has announced the acquisition of the licence for SRA737, a checkpoint kinase 1 (CHK1) inhibitor, in which the company had previously held a 27.5% economic interest. Following this acquisition... ► Artikel lesen | |
13.03. | Sareum Holdings PLC - Institutional Equity Fundraise | - | RNS | ||
13.03. | Sareum Holdings PLC - Sareum Acquires Licence for SRA737 | 2 | RNS | ||
31.12.24 | Sareum served notice on commercial licence for cancer treatment | 2 | Alliance News | ||
31.12.24 | Sareum shares drop on product licence termination | 4 | Sharecast | ||
31.12.24 | Sareum Holdings PLC - Update on SRA737 | 1 | RNS | ||
12.11.24 | Sareum Holdings - SDC-1801 prepping to enter Phase II | 353 | Edison Investment Research | Sareum Holdings' FY24 results summarised an active period for lead asset SDC-1801, a dual TYK2/JAK1 inhibitor, which successfully completed Phase I trials in Australia and is now undergoing preparatory... ► Artikel lesen | |
11.10.24 | Sareum Holdings - New funding extends runway to Phase II | 379 | Edison Investment Research | Sareum Holdings has announced the completion of a £2.4m private placement and receipt of another A$1.9m (c £1m) in R&D tax credits from Australian authorities, related to the Phase I clinical trial... ► Artikel lesen | |
02.07.24 | Sareum Holdings - SDC-1801 records positive Phase Ia data | 362 | Edison Investment Research | Sareum Holdings has announced positive top-line data from the Phase Ia clinical trial for SDC-1801, its lead asset, a novel TYK2/JAK1 inhibitor targeting autoimmune conditions. The results, which include... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
GSK | 16,510 | +0,24 % | GSK's Benlysta Autoinjector Gets FDA Approval For Children With Active Lupus Nephritis | LONDON (dpa-AFX) - GSK plc (GSK.L) Tuesday said that the U.S. Food and Drug Administration (FDA) has approved Benlysta autoinjector for individuals aged five years and older with active lupus... ► Artikel lesen | |
DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Provides Update Regarding Proposed RTO Transaction | / Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. ("Digicann" or... ► Artikel lesen | |
TONIX PHARMACEUTICALS | 29,000 | -2,68 % | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 1,768 | +6,89 % | SELLAS Life Sciences wird in Russell 3000 und Russell 2000 Indizes aufgenommen | ||
PLANTFUEL LIFE | 0,009 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 24.03.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.03.2025ISIN NameCA12571Q4034 CMC... ► Artikel lesen | |
ARGENT BIOPHARMA | 0,043 | -1,15 % | Argent BioPharma Ltd. Updates on SINTEF Collaboration for Chronic Wound Management | Advanced wound care market projected to exceed $15 billion globally by 2030
PERTH, Australia, Feb. 12, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT)... ► Artikel lesen | |
QUALIGEN THERAPEUTICS | 3,240 | -100,00 % | Qualigen Therapeutics ernennt Robert B. Lim zum Vorsitzenden des Prüfungsausschusses | ||
BAYER | 26,975 | +2,64 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
23.06.2025... ► Artikel lesen | |
MERCK KGAA | 112,65 | +0,90 % | MilliporeSigma and "Abbott Elementary" Inspire Students' Curiosity With Hands-On STEM | NORTHAMPTON, MA / ACCESS Newswire / June 25, 2025 / Between September 2024 and April 2025, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, teamed up with... ► Artikel lesen | |
NOVO NORDISK | 58,70 | +0,09 % | Novo Nordisk-Aktie: Geht es noch tiefer? | Die Aktie von Novo Nordisk hat nach ihrem monatelangen Abwärtstrend eine Erholung gezeigt, doch jetzt sieht es danach aus, als würde es erneut mit den Papieren nach unten gehen. Doch was steckt dahinter?... ► Artikel lesen | |
PFIZER | 20,665 | +0,02 % | Depot Verdoppler mit Künstlicher Intelligenz: Novo Nordisk, PanGenomic Health und Pfizer zünden 2025 den Profit-Turbo | Lauf BlackRock Health Sciences steht der globale Gesundheitssektor 2025 vor einem beispiellosen Aufschwung. Nach Jahren der Volatilität durch die Pandemie soll die Branche jetzt die höchsten Gewinnzuwächse... ► Artikel lesen | |
EYENOVIA | 10,960 | +38,91 % | Eyenovia launches validator node for Hyperliquid blockchain | ||
ROCKET LAB | 30,200 | -0,10 % | Rocket Lab Corporation: Rocket Lab to Launch Electron Mission for European Space Agency's Next-Generation Navigation System | Rocket Lab Corporation (Nasdaq: RKLB) ("Rocket Lab" or the "Company"), a global leader in launch services and space systems, today announced it has been selected to launch a dedicated Electron mission... ► Artikel lesen | |
ASTRAZENECA | 120,05 | +0,42 % | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca mit einem Kursziel von 14000 Pence auf "Overweight" belassen. Die beschleunigte US-Zulassung von Datroway gegen... ► Artikel lesen | |
DERMAPHARM | 34,750 | 0,00 % | EQS-DD: Dermapharm Holding SE: Dr. Andreas Eberhorn, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
24.06.2025 / 16:45... ► Artikel lesen |